tiprankstipranks

Evan Stein Insider Profile

4 Followers
Evan Stein, Director at Xenon, holds 100.00K shares in CymaBay Therapeutics (Ticker: CBAY), holds 4.17K shares in Xenon (Ticker: XENE).
tipranks
Evan Stein

Evan Stein
Xenon (XENE)
Director

Not Ranked
Evan Stein has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$169K
100.00%
A breakdown of Evan Stein's holdings

Insider Roles

Xenon
(XENE)
Director
Roles that Evan Stein holds in companies

Most Profitable Insider Trade

Currently, no data available
The most profitable trade made by Evan Stein

Evan Stein's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Xenon
May 04, 2015
Director
Uninformative Buy
$169.30K
CBAY
CymaBay Therapeutics
Apr 01, 2016
Uninformative Buy
$3.25M
List of latest transactions for each holding click on a transaction to see Evan Stein's performance on stock

Evan Stein insider profile FAQ

What is the percentage of profitable transactions made by Evan Stein?
The percentage of profitable transactions made by Evan Stein is ―.
    What is the average return per transaction made by Evan Stein?
    The average return per transaction made by Evan Stein is ―.
      What stocks does Evan Stein hold?
      Evan Stein holds: XENE, CBAY stocks.
        What was Evan Stein’s latest transaction?
        Evan Stein latest transaction was an Uninformative Buy of ―.
          What was Evan Stein's most profitable transaction?
          Evan Stein’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
            What is Evan Stein's role in Xenon?
            Evan Stein's role in Xenon is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.